What is the primary role of adjuvant therapy in postoperative management of head and neck cancer?

What is the primary role of adjuvant therapy in postoperative management of head and neck cancer?

• A. Observation with follow-up only.
• B. Radiation therapy or chemoradiation to reduce recurrence risk, depending on margins and pathology.
• C. Chemotherapy alone as prophylaxis.
• D. Immediate surgical resection of residual disease.

Answer: (B)

After surgery for head and neck cancer, the goal of adjuvant therapy is to mop up microscopic cancer cells that may remain in the surgical bed or neck tissues, thereby lowering the risk that the cancer will come back locally or regionally. The specific approach is guided by pathology and margins. If margins are positive or close and there are adverse features such as nodal involvement, extranodal extension, perineural invasion, or lymphovascular invasion, radiation therapy is used to target the at-risk areas, and it is often given with chemotherapy to act as a radiosensitizer and tackle potential micrometastatic disease. If margins are clear and the risk features are low, radiation alone may be sufficient to reduce recurrence risk. Chemotherapy alone is not the standard adjuvant strategy here because the aim is to maximize local-regional control with radiotherapy, using chemotherapy mainly as a concurrent sensitizer in higher-risk situations. If there is gross residual disease after surgery, that scenario is typically addressed with salvage procedures or definitive therapy rather than adjuvant treatment aimed at microscopic residual disease.

After surgery for head and neck cancer, the goal of adjuvant therapy is to mop up microscopic cancer cells that may remain in the surgical bed or neck tissues, thereby lowering the risk that the cancer will come back locally or regionally. The specific approach is guided by pathology and margins. If margins are positive or close and there are adverse features such as nodal involvement, extranodal extension, perineural invasion, or lymphovascular invasion, radiation therapy is used to target the at-risk areas, and it is often given with chemotherapy to act as a radiosensitizer and tackle potential micrometastatic disease. If margins are clear and the risk features are low, radiation alone may be sufficient to reduce recurrence risk. Chemotherapy alone is not the standard adjuvant strategy here because the aim is to maximize local-regional control with radiotherapy, using chemotherapy mainly as a concurrent sensitizer in higher-risk situations. If there is gross residual disease after surgery, that scenario is typically addressed with salvage procedures or definitive therapy rather than adjuvant treatment aimed at microscopic residual disease.